Hexarelin Dosage: Why Protocols Use Short Cycles
Last updated May 19, 2026 · Reviewed by Grey Peptides Editorial Board · ✓ Primary-sourced
← Hexarelin encyclopedia entry · See also: GHRP-6 dosage · GHRP-2 dosage
Hexarelin is investigational and was never FDA approved. There is no label or official dose. The figures below reflect community practice, documented for education — not instructions for use. An unapproved injectable carries unknowns of identity, purity, and sterility.
The short version
Hexarelin is a potent growth-hormone-releasing peptide, closely related to GHRP-6 but more resistant to breakdown. Its defining practical issue is tachyphylaxis — with continued use, the GH response fades as receptors desensitize. That single pharmacologic fact is why hexarelin protocols look different from the others: they emphasize short cycles rather than ongoing daily use.
What community protocols report
| Parameter | Commonly reported |
|---|---|
| Amount | ~100–300 mcg per dose |
| Frequency | 1–2× daily |
| Pattern | Short cycles only (to limit desensitization) |
| Route | Subcutaneous |
The short-cycle emphasis is the whole point: because the GH response diminishes over time, continuous dosing is thought to yield diminishing returns. This is reasoning carried over from hexarelin's known desensitization, not a validated human schedule.
Hexarelin is among the most potent GHRPs for an acute GH pulse, but the desensitization issue limits its sustained usefulness — a trade-off that the more selective ipamorelin avoids. There have also been research observations of hexarelin acting at other receptors (including in cardiac tissue), which is part of why it is treated cautiously. See the GHRP-6 and GHRP-2 dosage pages for family context.
Reconstitution basics
Hexarelin is supplied as a lyophilized powder requiring reconstitution with bacteriostatic water before microgram doses can be measured. The Reconstitution Calculator converts vial strength and diluent volume into an exact draw; it cannot verify what is in an unregulated vial.
Frequently asked questions
What is tachyphylaxis, in plain terms?
It means the body responds less and less to the same dose over time as the receptors adapt — so the effect you get in week one is not the effect you get after sustained use.
Is hexarelin stronger than GHRP-6?
It is generally considered more potent for an acute GH release, but the desensitization and broader receptor activity make it less suited to continuous use.
Is it legal?
It is not an approved medicine; it circulates as a research compound, and status varies by jurisdiction — see the Regulatory Status Tracker.
Sources
- Ghigo E, Arvat E, et al. Growth hormone-releasing activity of hexarelin in humans.
- Reviews of GHRP pharmacology, desensitization, and non-GH receptor effects.
Medical disclaimer: Education only, not medical advice. Hexarelin is investigational and not approved for human use. Dosing figures reflect community practice, not a recommendation. Do not self-administer; consult a licensed clinician.